FDA Grants Priority Review for Vorasidenib in IDH-Mutant Diffuse Glioma
Katherine Peters, MD, PhD
Dr. Peters was quoted from an interview with Targeted Oncology where she spoke about the improved prognosis in brain tumor patients that had received vorasidenib.
